Yes indeed, small "s" (safety) indications are primary, and

New Post Public Reply Private Reply Replies (4) Message Board
skorogi seel #6255

Yes indeed, small "s" (safety) indications are primary, and we don't even have the first pk data, only very early indications of low "t" (toxicity). After enough small s occurrences, escalating doses will achieve and quantify MTD (maximum tolerable dose). Other markers are likely known with the first pk analysis, but as yet undisclosed. One would look for these first labs to show "something" related to "e" (efficacy) even before MTD is achieved. In the absence of data, continued cohorts and dose escalation are good signs.

Clearly, statistical significance (robust N) becomes crucial to a big "E" disclosure, but many will be looking carefully at even the smallest cohort sizes, and regardless of N (number of subjects) whatever the first two pk labs samples show will carry some significant implications (of possible small "e" evidence).

What level of data from labs/scans will be disclosed and when? We don't know... this is up to DF (not publications/journals). However, once evidence from cumulative trials positively correlates activated p23 with MRI scans showing decreased tumor size-- then we have arrived, i.e. efficacy with a capital E.

As an investor, if I wait for such positive efficacy evidence to be disclosed, I will no doubt have missed a significant SP move based on a series of prior small "e' evidence. But here's the caveat: one or two, or even a series of small positive markers (e) does not necessarily add up to a Big E. Hence, I fear ongoing vulnerability to whiplash, head-fakes and churn as sequential data points are released.

Which brings us back to issues of hype, volatility and MMs. No doubt we have only seen the first glimpses of a volatile SP, in part because of the sharp rise last month, in part because this is becoming a "story stock" on the OTC. CTIX is in a hot sector (M&A), has multiple novel small molecule drugs, has reputable sponsored trials, expert medical advisory lineage, favorable recent financing, etc.

But here we are on the OTC (wild-west). The MMs love volatility and we saw it again on Friday. They can get away with obvious BS due to lack of regulation, and crying foul can be expensive and distracting to the company (especially if they sue the investment banks/brokerages who are playing games). This does not mean we should hold back from complaining to FINRA when necessary, as it is important for investors to keep the heat on these "regulators."

But the better answer to these "erratic MMs" is to up-list as soon as possible. The volatility will continue here on the OTC and may even get "worse" (both up and down). Traders always try to use the MMs manufactured volatility to their advantage here in the wild-west, but longer-term investors just get tummy aches. The only way to get a fair(er) shake is by getting on a "real" exchange (Leo should consider starting now to be ready with requirements for when the SP stays above $2 for 30 days).

Of course, some people enjoy rollercoaster rides on the OTC and are nimble enough to make money off the swings. But for many who choose to endure the ride (loyal longs) I am certain there will continue to be the occasional need for Dramamine and small white bags.

Back to my shorthand: "small" and "big" letter categories for safety and efficacy might seem like a stretch, but each domain has its own continuum of gradations. Thus, I feel these are useful metaphors designating "incrementally increasing positive markers" (for both small s and e) that will hopefully accrue and morph into a big "E" sometime later this year (for both kevetrin and prurisol).

In sum: small "s" is a necessary but not a sufficient condition for "e"... but glimmers of "e" should be observed even before bigger S arrives with MTD. Clearly, the more signs of little s's and e's the better. I have my magnifying glass out, but its more difficult being many time zones away.

Best to all longs here.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 11

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 43

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 16

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 234

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 114

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Microsoft-Intel Azure Pact Puts Systems Work First

Updated Category News Views 18

Azure’s next bottleneck may be the plumbing between chips, not the chips alone. Microsoft and Intel announced on Nov. 18, 2026, a long-term expansion of their already ancient partnership aimed at shaping select pieces of Azure infrastructure for cloud and AI demand. That sounds dry, because infrastructure announcements usually do. But this one deserves a closer look: it...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 134

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Generative AI Chipset Market Growth

Updated Category News Views 252

Generative AI Chipset Market Size Analysis The Generative AI Chipset Market is experiencing remarkable growth as the demand for high-performance AI hardware accelerates across various industries. Currently valued at approximately USD 37.29 billion in 2023, the market is anticipated to reach an impressive USD 454.50 billion by 2032, representing a staggering compound...

Continue Reading
CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer

Updated Category News Views 297

CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer CrateDB, the groundbreaking real-time database solution designed for analytics, search, and AI applications, has announced the exciting appointment of Robert Ekstrom as the new Chief Executive Officer. His leadership is viewed as a pivotal moment for the company, propelling its growth strategies and...

Continue Reading
Novartis AGM Highlights: Board Changes and Dividend Increase

Updated Category News Views 463

Key Outcomes from Novartis' Annual General Meeting Today, Novartis held its Annual General Meeting (AGM) where shareholders gathered to discuss and approve various resolutions proposed by the Board of Directors. It was an important day for the company, as a strong turnout highlighted investor engagement and confidence. Dividend Increase for 2024 This year marks a...

Continue Reading
Understanding Alliance Witan PLC's Net Asset Valuation Insights

Updated Category News Views 116

Understanding Alliance Witan PLC's Financial Standing Alliance Witan PLC stands out in the investment landscape, offering its shareholders a detailed look at their Net Asset Value (NAV). As of the latest reporting date, the financial metrics reveal significant information pertaining to the company's performance and shareholder value. Net Asset Value Calculation At the...

Continue Reading
Remembering Jimmy Carter: A Legacy of Service and Humanity

Updated Category News Views 375

Remembering Jimmy Carter: A Legacy of Service and Humanity Habitat for Humanity joins millions around the globe in reflecting on the remarkable life of former U.S. President Jimmy Carter. He is widely recognized not only as a political leader but also as a formidable advocate for affordable housing. A Champion for Affordable Housing Throughout his life, President Carter...

Continue Reading